Role of immunohistochemical markers in breast cancer and their correlation with grade of tumour, our experience

Abstract

Objectives: To study the immunohistochemical markers in invasive carcinoma of breast and to assess the relationship of hormonal receptors and Her2Neu oncoprotein with grade of tumour.

Materials and methods: This was a comparative cross sectional study conducted at Chughtais Lahore lab from Jan 2011–Oct 2011. Eighty two biopsy proven cases of breast carcinoma were reviewed. Immunohistochemistry was used to evaluate the expression of Estrogen receptors (ER) and progesterone receptors (PR) and Her2Neu oncoprotein. Grade of tumour was assessed by Scarf Bloom Richardson Grading system.

Results: This study comprised 82 cases of invasive breast carcinoma. Out of these 82 cases, 2 were males and 80 were females. Majority of the cases were between 25–45 years age group. Fifty seven cases (69.5%) were of grade 2 and 25 cases were of grade 3(30.4%) cases. There was no grade 1 tumour in our study. Considering ER, PR and Her2Neu oncoprotein overexpression and grade of tumour, twenty five cases (30.4%) were ER+ PR+ and Her2Neu negative and were all grade 2. Eleven cases (13%) were ER– PR– and Her2Neu– and were grade 2. Only one case(1.2%) was ER– PR+ and Her2Neu– and was again grade 2. Eight cases (9.7%) were triple negative with grade 3 morphology. Twenty seven cases were ER– PR– and Her2Neu positive (32.9%). Eleven cases were ER+ PR– and Her2Neu+ with grade 2 morphology and 16 cases were grade 3. Ten cases (12.1%) were triple positive having 9 cases with grade 2 morphology and one case with grade 3 morphology.

Conclusion: Reactivity of steroid receptors decreases with increasing grade. Triple negative tumours usually exhibit higher grade. HER2 Neu positivity is also associated with higher grade and poor survival rate.

Keywords: estrogen receptor, progesterone receptor, her2 neu, breast carcinoma

Introduction

Breast cancer is a major concern and one of the leading causes of cancer related death worldwide. Breast cancer like many other types of cancer is a complex heterogeneous disease controlled by a multitude of genetic and epigenetic alterations.1 In Pakistani females, breast carcinoma occurs at a younger age group. Infiltrating ductal carcinoma is the most common type of tumour.2 Male breast carcinoma is an uncommon disease.3 Less than 1% of all breast carcinomas occurs in men.4 The pathology is similar to that of female breast cancer, and infiltrating ductal cancer is the most common tumor type.6 During the past two decades the mortality rate has declined significantly, primarily due to the early use of adjuvant chemotherapy as well as detection of earlier stage tumours due to increased screening.7,8 Prognosis and management of breast cancer is influenced by the classical variables such as histological type and grade, tumour size, lymph node status, and status of hormonal receptors. Estrogen receptors (ER) and progesterone receptors (PR) of the tumour and more recently Her2Neu oncoprotein status.9,10 ER expression is undoubtedly the most important biomarker in breast cancer, because it provides the index for sensitivity to endocrine treatment. ER positive tumours (80% of breast cancer) use the steroid hormone estradiol as their main growth stimulus; ER is therefore direct target of endocrine therapies. PR expression is strongly dependent on the presence of ER. Tumours expressing PR but not ER are uncommon and represent <1 % of all breast cancer.11 The proto–oncogene (C–erb) has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase growth factor receptor. The name for the Her2 Neu is derived from human epidermal growth factor receptor, as it features substantial homology with the epidermal growth factor receptor (EGFR).11,12 Amplification and/or overexpression of Her2/ Neu gene is routinely evaluated using immunohistochemistry and/or fluorescence insitu hybridization (FISH) in all cases of invasive breast carcinoma. Her–2 Neu amplification occurs in about one quarter to one fifth of breast cancers.13 The purpose of this study was to analyze the immunohistochemical markers in invasive carcinoma of breast and to assess the relationship of hormonal receptor status and Her2 Neu oncoprotein over expression with tumour grade.

Materials and methods

This was a comparative cross sectional study conducted at Chughtais Lahore lab from Jan 2011–Oct 2011. Eighty two biopsy proven cases of breast carcinoma were reviewed. Immunohistochemistry was used to evaluate the expression of ER, PR and Her2Neu oncoprotein. The immunohistochemistry for ER, PR and Her2Neu was done on paraffin
embedded blocks using primary monoclonal antibodies (Dako), for hormonal staining, Altfred score was used which is semi-quantitative system that takes into consideration the proportion of positive cells (scored on a scale of 0–5) and staining intensity (scored on a scale of 0–3). The proportion and intensity were then summed to produce total scores of 0 or 2 through 8. A score of 0–2 was regarded as negative while 3–8 as positive. Inbuilt control i.e. normal breast tissue was evaluated for ER staining wherever included with tumour.14,15 The scoring system for Her2Neu was assessed as negative for scores of 0 & 1+ and positive for scores of 2+ and 3+. On the basis of ER, PR, and Her2 Neu expression, the patient divided into six groups: ER+ve/PR+ve, Her2 Neu –ve, ER+ive PR–ve and Her2 Neu –ve, ER–ve PR+ve and Her2 Neu –ve, ER+ve/PR+ve and Her2 Neu +ve and ER–ve PR–ve Her2 Neu +ve and ER–ve, PR–ve Her2 Neu –ve. Histological grade was calculated by modified Bloom–Richarson System (MBR) and divided into three grades (Grade 1–3).16,17

Results

This study comprised 82 cases of invasive breast carcinoma. Out of these 82 cases, two were males and 80 were females. Age range was between 25–85 years. Regarding age group distribution, three age groups were made, First group (25–45 years), second group (46–65 years), third group (66–85 years). Forty one cases belonged to first group. Thirty one cases were of second group and only eight cases belonged to third group. However, the only two males included in this study belonged to second group. More than half of the cases are ER positive (Table 1). Majority of the cases belonged to grade 2 (Table 2). No grade 1 tumour was present in our study. Fifty seven cases (69.5%) were of grade 2 and 25 cases were of grade 3 (30.4% cases). Considering ER, PR and Her2Neu oncoprotein overexpression and grade of tumour, twenty five cases (30.4%) were ER+ PR+ and Her2Neu negative and were all grade 2. Eleven cases (13%) were ER+ PR–and Her2Neu–and were grade 2. Only one case (1.2%) was ER– PR+ and Her2Neu–and was again grade 2. Eight cases (9.7%) were triple negative with grade 3 morphology. Twenty seven cases were ER– PR–and Her2Neu positive (32.9%). Eleven cases (13.4%) were ER–PR– and Her2Neu + with grade 2 morphology and 16 cases were grade 3. Ten cases (12.1%) were triple positive having 9 cases with grade 2 morphology and one case (1.2%) with grade 3 morphology.

Table 1 Percentage of different Immunohistochemical markers

| Immunohistochemical marker | Number of patients | Percentage |
|---------------------------|-------------------|-----------|
| ER                         | 46                | 56%       |
| PR                         | 36                | 43.90%    |
| Her2Neu                    | 37                | 45.10%    |

Discussion

Breast cancer is the most common cancer with increased mortality rate. In addition to pathological grade and stage, breast cancers are routinely assessed for hormone receptor status (ER) by immunohistochemistry and human epidermal growth factor receptor2 (HER2) expression by IHC or amplification by FISH in order to guide the choice of the appropriate adjuvant therapy.18 The aim of our study was to identify the common immunohistochemical markers in invasive breast carcinoma and to find out the relationship between hormonal receptor status and Her2Neu overexpression with the grade of tumour. This is routinely done in every case of invasive breast carcinoma because patients with ER positive primary breast tumours are offered adjuvant hormone therapy, routinely tamoxifen for five years, while post menopausal women may receive aromatase inhibitor. Patients with overexpression of Her2 Neu are eligible for trastuzumab, a mAb that targets the Her2 Neu receptor19,20.

Breast carcinoma is the most common carcinoma in women and accounts for 22% of all female cancers which is more than twice the prevalence of cancer in women at any other site. In our study both male and female breast cancers were included and out of 82 cases only two were males.21 While in most of other studies either only female breast carcinomas were assessed or only male breast carcinomas.

In our study mostly patients were below 50 years of age which is quite similar to many local and international studies.5,22,23 Estrogen receptor is expressed in 70–80% of invasive ductal carcinoma, while PR is expressed in 60–70% of invasive breast carcinoma.4 In our study the ER was expressed in 56% of cases. While PR was expressed in 43.9% of cases and Her2Neu was expressed in 45.1% of cases. The expression of ER and PR is quite comparable to many international and local studies. The study conducted by Fatima et al.,25 showed ER positivity to be 52.4% very close to our study. Similarly a study conducted in India by Desai et al.,27 showed ER positivity in 33% of cases, 46% were PR positive. In their study ER and PR immune reactivity increased with advancing age. Ranatunga et al.,26 observed ER and PR positivity in 53% and 50% of cases respectively. Yip et al.,27 reported that 50% of the cases were ER positive. Ong et al.,22 reported 60% of the cases were ER positive. This may be because of the reason that most of the patients in our study were between 25–45 years and in premenopausal age group where ER positivity is lower and it increases in post– menopausal age group and carcinomas were of high grade. In Nigerian woman, the most common reason for delayed presentation was fear of mastectomy with similar reasons identified by women from Pakistan.21 Considering the joint ER and PR positivity, in our study it was 30.4% while in the study by Desai et al.,25 it was 25%. In study by Ranatunga et al.,26 it was 44%. While in

**Table 2 Comparative incidence of frequency of hormone receptor status**

| Hormone receptor | Suvarchala et al.22 | Bhagat et al.30 | Gethamala et al.18 | Present study 2016 |
|------------------|---------------------|-----------------|--------------------|-------------------|
| ER+/PR+ Her2 Neu –ve | 32.8                | 36.20           | 52                 | 30                |
| ER+/PR– Her2 Neu –ve | 14                  | 12.06           | 2                  | 13                |
| ER–/PR+ Her2 Neu –ve | 10.94               | 1.72            | 0                  | 1.2               |
| ER–/PR– Her2 Neu +ve | –                   | 27.85           | 25                 | 32.9              |
| Triple positive   | –                   | 2              | 1                  | 12                |
| Triple negative   | 42.19               | 25.86           | 20                 | 9.7               |
local studies like Sharif et al., the joint expression was 73.8% which is quite higher. A study conducted by Geethamala, it was 52% while by Bhagat et al., it was 36.2% and in a study by Suvarchala et al., it was 32.8%.

The frequency of Her2/Neu reactivity is 45.1% which is very much higher but is close to many international and local studies. In a study by Sharif et al., the Her2/Neu positivity was seen in 31% of cases. In a study conducted by Geethamala, it was 25%. Lack of knowledge regarding necessity to visit, fear, negligence, lack of access to physicians and poverty are main reasons for delay. In our study triple positive cases were 12% while in studies conducted by others, the number is none to one (Table 2). They attributed this to differences in techniques of evaluation, higher tumour grades and majority being menopausal women. The two males included in this study were ER and PR receptors negative and were positive for Her2Neu over expression. In our study most tumours were of grade 2 which is again in concordance with many of the studies (Table 3). Considering the grade of tumour and hormonal receptors, mostly patients were of grade 2 and were hormonal receptors positive which is in concordance with study by Baswal et al. In our study there were no grade 1 tumours while in other studies (Table 4), there were cases of grade 1 and those were again hormonal receptors positive. While in the study by Biswal et al., there were also no grade 1 tumours. In our study grade 3 tumours were either triple negative, triple positive or Her2Neu positive which is again in concordance with other studies (Table 4). However we didn’t have any case of grade 3 with hormone receptor positivity which is against other studies.

### Table 3

| Grade of the tumor | Suvarchala et al. | Bhagat et al. | Shafaq et al. | Javeria et al. | Geethamala et al. | Mushood et al. | Present study 2016 |
|-------------------|------------------|--------------|--------------|----------------|------------------|----------------|-------------------|
| 1                 | 28.12            | 27.58        | 18           | 19             | 9.3              | –              |                   |
| 2                 | 42.18            | 43.1         | 45           | 53.9           | 54               | 46.7           | 69.5              |
| 3                 | 29.69            | 29.31        | 37           | 40.6           | 27               | 43.8           | 30.5              |

### Table 4

| Study             | Grade of tumor and Hormone receptor tumor |
|-------------------|------------------------------------------|
|                   | Grade 1                                  | Grade 2                                  | Grade 3                                  |
|                   | ER+/PR+ 78.9%                            | ER+/PR+ 64.9%                            | ER+/PR+ 7.4%                             |
| Geethamala²        | ER+/PR−ve 5.3%                           | ER+/PR−ve 1.8%                           | ER+/PR−ve 0%                             |
| N = 100           | ER−/PR+ 0%                               | ER−/PR+ 0%                               | ER−/PR+ 0%                               |
|                   | ER−/PR−/Her2Neu + 15.8%                  | ER−/PR−/Her2Neu + 27.8%                  | ER−/PR−/Her2Neu + 26.4%                  |
|                   | Triple negative 0%                       | Triple negative 62.9%                   | Triple negative 62.9%                   |
|                   | Triple positive 0%                       | Triple positive 5.5%                    | Triple positive 3.3%                    |
|                   | ER+/PR+ 33.3%                            | ER+/PR+ 51.85%                           | ER+/PR+ 5.26%                            |
|                   | ER+/PR−ve 5.5%                           | ER+/PR−ve 18.5%                          | ER+/PR−ve 15.7%                          |
|                   | ER−/PR− 5.5%                             | ER−/PR− 7.41%                            | ER−/PR− 21.05%                           |
|                   | ER−/PR− 55.5%                            | ER−/PR− 22.2%                            | ER−/PR− 57.8%                            |
|                   | ER+ 16.93% ER−ve 16.1%                   | ER +24.62% ER−ve 26.9%                  | ER +0.7% ER−ve 14.6%                    |
| RituYadev et al.³ | PR+ 15.38% PR−ve 17.7%                   | PR+ 22.31% PR−ve 30.7%                  | PR+ 1.54% PR−ve 12.31%                  |
| N = 150           | Her2Neu + 20.7%                          | Her2Neu +27.7% Her2Neu−ve 20%           | Her2Neu +9.24% Her2Neu−ve 7.69%         |
|                   | Her2Neu−ve 14.6%                         |                                           |                                           |
|                   | ER+/PR+ 5.7%                             | ER+/PR+ 21.5%                            | ER+/PR+ 15.1%                            |
|                   | ER+/PR−ve 0.7%                           | ER+/PR−ve 3.5%                           | ER+/PR−ve 2.8%                           |
|                   | ER−/PR+ 0.7%                             | ER−/PR+ 2.1%                             | ER−/PR+ 4.3%                             |
|                   | ER−/PR−/Her2Neu + 2.1%                   | ER−/PR−/Her2Neu + 19.4%                  | ER−/PR−/Her2Neu + 21.5%                  |

Citation: Afzal N, Khalid M, Chughtai O. Role of immunohistochemical markers in breast cancer and their correlation with grade of tumour, our experience. Int Clin Pathol J. 2018;6(3):141–145. DOI: 10.15406/icpjl.2018.06.00175
Table continued

| Study                          | Grade of tumor and Hormone receptor tumor |
|-------------------------------|------------------------------------------|
|                               | ER+/PR+ 30.4%                           |
|                               | ER+/PR–ve 13%                           |
|                               | ER–/PR+ 1.2%                            |
|                               | ER–/PR– /Her2Neu + 13.4%                |
|                               | Triple negative 0%                      |
|                               | Triple positive 10.9%                   |
| Present Study 2016 N= 82      | ER+/PR+ 30.4%                           |
|                               | ER+/PR–ve 13%                           |
|                               | ER–/PR+ 1.2%                            |
|                               | ER–/PR– /Her2Neu + 19.5%                |
|                               | Triple negative 9.7%                    |
|                               | Triple positive 1.2%                    |

Conclusion

Reactivity for steroid receptors was observed to be decreasing with increasing grade. Grade III tumor were more receptor status negative as compare to grade I and grade II tumor. This showed the same inverse relation between receptor status and increasing tumor grade.

Acknowledgements

None.

Conflict of interest

The author declares that there is none of the conflicts.

References

1. Yadav R, Sen R, Preeti. Role of receptors in breast cancer. *LJABR*. 2012;2(4):561–571.
2. Siddiqui MS, Kayani N, Sulaiman S, et al. Breast carcinoma in Pakistani females; a morphological study of 572 breast specimens. *J Pak Med Assoc*. 2000;50(6):174–177.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics. *CA cancer J Clin*. 2007;57(1):43–66.
4. Borgen PI, Wong GY, VlamisV, et al. Current management of male breast cancer. A review of 104 cases. *Ann Surg*. 1992;215(5):451–457.
5. Fentiman IS, Fouquet A, Hortobagyi GN. Male breast cancer. *Lancet*. 2006;367(9510):595–604.
6. Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: De Vita VT, Lawrence TS, editors. *Rosenberg SA: Cancer: Principles and Practice of Oncology*. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009;14(4):320–368.
7. Jatoi I, Miller AB. Why is breast cancer mortality declining? *Lancet Oncol*. 2003;4(4):251–254.
8. Sharif MA, Mamoon N, Mushq S, et al. Morphological profile and association of Her –2 Neu with prognostic markers in breast carcinoma in Northern Pakistan. *J Coll Phy Surg Pak*. 2009;19(2):99–103.
9. Rastelli F, Crispino S. Factors predictive response to hormone therapy in breast cancer. *Tumouri*. 2008;94(3):370–383.
10. Weigol MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. *Endocr Relat Cancer*. 2010;17(4):245–262.
11. Ross JS, Fletcher JA. The Her2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. *Stem Cells*. 1998;16(6):413–428.
12. Ross JS, Slodkowska EA, Symmans WF, et al. The Her–2 receptor and breast cancer: ten years of targeted anti Her2 therapy and personalized medicine. *Oncologist*. 2009;14(4):320–368.
13. Huang HJ, Neven P, Drijkoningen M, et al. Hormone receptors donot predict the Her2/neu status in all age groups of women with an operable breast cancer. *Ann Oncol*. 2005;16(11):1755–1761.
14. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, editors. *Diseases of the Breast*. Philadelphia: Lippincott–Raven; 1996. p. 461–485.
15. Collins LC, Botero ML, Schmitt SJ. Bimodal frequency distribution of Estrogen Receptor immunohistochemical staining results in breast cancer. *Am J Clin Pathol*. 2005;123(1):16–20.
16. Iqbal J, Abukhairi M, Shafi A, et al. Hormone receptor status of breast cancer in patients of different age groups, lymph node status histological type and tumour grade, an experience at King Fahad Medical City, Riyadh. *Pak J Surg*. 2014;30(4):296–300.
17. Gupta D, Gupta V, Marwah N, et al. Correlation of hormone receptor expression with histologic parameters in benign and malignant breast tumors. *Ir J Pathol*. 2015;10(1):23–34.
18. Payne SJ, Brown RL, Jones JL, et al. Predictive markers in breast cancer—the present. *Histopathology*. 2008;52(1):82–90.
19. Aitken SJ, Thomas JS, Langdon SP, et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasis. *Ann Oncol*. 2010;21(6):1254–1261.
20. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. *Mod Pathol*. 2008;21 Suppl 2:S8–S15.
21. Lal P, Tan LK, Chen B. Correlation of Her2/neu status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. *Am J Clin Pathol*. 2005;123(4):541–546.
22. Ong TA, Yip CH. Short term survival in breast cancer: The experience of the university of Malaya Medical centre. *Asian J Surg*. 2003;26(3):169–175.
23. Suvarchala SB, Nageswara Rao R. Carcinoma breast–histopathological and hormone receptors correlation. *J Biosci Tech*. 2011;2:380–384.
24. Fatima S, Faridi N, Gill S. Breast cancer. Steroid receptors and other prognostic indicators. *J Coll Phy Surg Pak*. 2004;15(4):230–233.
25. Desai SB, Moonim MT, Gill AK, et al. Hormone receptor status of breast cancer in India: A study of 798 tumours. *Breast*. 2000;9(5):267–270.
26. Ranatunga N, Liyanapathirana LV. Hormone receptor expression and Her2/neu amplification in breast carcinoma in a cohort of SriLankans. *Cytol Med J*. 2007;52(4):133–136.
27. Yip CH, Taib NA, Mohamed I. Epidemiology of breast cancer in Malaysia. *Asian Pac J Cancer Prev*. 2006;7(3):130–133.
28. Bhikoo R, Srinivasa S, Yu TC, et al. Systemic review of breast cancer biology in developing countries (part 2): Asian Subcontinental and South East Asia. *Cancers (Basel)*. 2011;3(2):2382–2401.
29. Geethamala K, Srinivasa Murthy V, BR Vani, et al. Histopathological Grade versus hormone receptor status in breast carcinoma treasure the past. *International journal of biomedical research.* 2015;8(7):466–471.

30. Bhagat Vasudha M, Jha Bharti M, Patel Prashant R. Correlation of hormonal receptor and her2 neu expression in breast cancer: A study at tertiary care hospital in south Gujarat. *National Journal of medical research.* 2012;2(3):295–298.

31. Mujtaba S, Haroon S, Faridi N, et al. Correlation of human epidermal growth factor receptor 2 (Her–2/neu) receptor status with hormone receptors Oestrogen receptor, progesterone receptor status and other prognostic markers in breast cancer: an experience at tertiary care hospital in Karachi. *JPMA.* 2013;63(7):854–858.

32. Nabi MG, Ahangar A, Kaneez S. Estrogen receptors, progesterone receptors and their correlation with respect to Her–2/neu status, histological grade, size of lesion, lymph node metastasis, lymphovascular involvement and age in breast cancer patients in a hospital in north India. *Asian Journal of Medical Sciences.* 2016;7(3):28–34.

33. Baswal P, Behera S, Kar A, et al. Correlation of hormonal receptors estrogen receptor, progesterone receptor and Her2 Neu with tumor characteristics in breast carcinoma: Study of 100 consecutive cases. *International Journal of Clinical Medicine.* 2015;6:961–966.

34. Yadav R, Sen R, Chauhan P. ER, PR, Her2/Neu status and relation to clinicopathological factors in breast carcinoma. *Int J Pharm Pharm Sci.* 2016;8(4):287–290.

35. Amit M, Parasad C, Sreeramulu P. Histopathological grade versus Estrogen and progesterone receptor status in carcinoma breast–A single centre study. *Open Access J Surg.* 2017;4(3):555–639.

**Citation:** Adif N, Khalid M, Chughtai O. Role of immunohistochemical markers in breast cancer and their correlation with grade of tumour, our experience. *Int Clin Pathol J.* 2018;6(3):141–145. DOI: 10.15406/icplj.2018.06.00175